Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NCOA4
REST API REST API
Homo sapiens
NCOA4 is differentially expressed in 243 experiments: 90 organism parts: bone marrow, liver, ... (88 more);, 178 disease states: normal, acute myeloid leukemia, ... (176 more);, 77 cell types 280 cell lines 24 compound treatments and 73 other conditions.
Synonyms ELE1, PTC3, RFG, ARA70, DKFZp762E1112
Orthologs NCOA4 (Danio rerio)   Q5ZMB1_CHICK (Gallus gallus)   Ncoa4 (Mus musculus)   Q1RMQ8_BOVIN (Bos taurus)   Ncoa4 (Rattus norvegicus)   NCOA4 (Xenopus laevis)   NCOA4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term male gonad development, transcription coactivator activity, nucleus, response to hormone stimulus, receptor activity, positive regulation of transcription, DNA-dependent, mitochondrion, androgen receptor binding, androgen receptor signaling pathway
UniProt Accession Q96E88, Q13772, C9J6E0, Q6TAR0, B4DZ85, A8K8W5, B1API7, Q8NI67, B4DF87, E9PAV7
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY
InterPro Term ARA70
Search EB-eye ENSG00000138293
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, E-MTAB-62, ... (25 experiments)

Factor Value U/D Experiments
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MDA-MB-231
2
E-TABM-420, E-MTAB-62
U87
2
E-MEXP-903, E-GEOD-20089
Capan2
1
E-MTAB-37
KMS20
1
E-MTAB-62
274 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-360, ... (39 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-3982, E-GEOD-360
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CXCR5(-)ICOS(-/lo) CD4 T cell
1
E-MEXP-750
CD56+ NK cells
1
E-AFMX-5
basophil
1
E-GEOD-3982
dermal fibroblast
1
E-MEXP-1216
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-5370, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
neuroblastoma
2
E-MTAB-62, E-MTAB-37
locally advanced breast carcinoma
1
E-MTAB-62
adenocarcinoma (poorly differenciated)
1
E-MTAB-62
172 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-5824, E-GEOD-15811, E-GEOD-5099, E-GEOD-6462, ... (18 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-GEOD-2803, E-GEOD-20719, ... (6 experiments)
AMP
1
E-MEXP-2285
heregulin
1
E-GEOD-6462
BCR/FGFR1
1
E-GEOD-15811
Cxcl12
1
E-GEOD-7307
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847

Genotype
studied in E-GEOD-2466, E-GEOD-21750, E-GEOD-22593, E-TABM-43, E-TABM-868, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-20540, E-GEOD-20504, E-TABM-440, E-MEXP-1273 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-7114, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-1643, E-GEOD-2508, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43

Processing time: 0.379 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM